[go: up one dir, main page]

AU2001234730A1 - Method for inhibiting complement activation - Google Patents

Method for inhibiting complement activation

Info

Publication number
AU2001234730A1
AU2001234730A1 AU2001234730A AU3473001A AU2001234730A1 AU 2001234730 A1 AU2001234730 A1 AU 2001234730A1 AU 2001234730 A AU2001234730 A AU 2001234730A AU 3473001 A AU3473001 A AU 3473001A AU 2001234730 A1 AU2001234730 A1 AU 2001234730A1
Authority
AU
Australia
Prior art keywords
complement activation
inhibiting complement
inhibiting
activation
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234730A
Inventor
Agnes M. Azimzadeh
Todd D. Giorgio
Richard N. Pierson
Simon Robson
George L. Zorn Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Vanderbilt University
Original Assignee
Beth Israel Deaconess Medical Center Inc
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Vanderbilt University filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2001234730A1 publication Critical patent/AU2001234730A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001234730A 2000-02-01 2001-02-01 Method for inhibiting complement activation Abandoned AU2001234730A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17954300P 2000-02-01 2000-02-01
US60179543 2000-02-01
PCT/US2001/003296 WO2001057184A2 (en) 2000-02-01 2001-02-01 Use of platelet activity modulators for inhibiting complement activation

Publications (1)

Publication Number Publication Date
AU2001234730A1 true AU2001234730A1 (en) 2001-08-14

Family

ID=22657027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234730A Abandoned AU2001234730A1 (en) 2000-02-01 2001-02-01 Method for inhibiting complement activation

Country Status (3)

Country Link
US (2) US6538028B1 (en)
AU (1) AU2001234730A1 (en)
WO (1) WO2001057184A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057184A2 (en) * 2000-02-01 2001-08-09 Vanderbilt University Use of platelet activity modulators for inhibiting complement activation
US6716962B2 (en) * 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20040244062A1 (en) * 2003-06-02 2004-12-02 Crittenden Jill R. Use of protein inhibitors as antithrombotic agents
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
SI1755674T1 (en) * 2004-05-14 2015-04-30 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
NZ570802A (en) * 2006-03-02 2012-03-30 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
WO2010032073A1 (en) 2008-09-16 2010-03-25 Ak Kimya Ithalat-Ihracat Ve Sanayii Anonim Sirketi Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
TR201203732T1 (en) * 2009-10-01 2012-09-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Topical compositions of opioid antagonists and methods for the treatment of skin diseases with such compositions.
TR201002473A2 (en) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. A method of treating herpes zoster disease using an opiate receptor antagonist.
US10588879B2 (en) 2011-08-01 2020-03-17 Aurin Biotech Inc. Treatment of age-related macular degeneration
US10966945B2 (en) 2011-08-01 2021-04-06 Aurin Biotech Inc. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
EP2872130A4 (en) * 2012-07-13 2016-06-22 Aurin Biotech Inc Selective inhibition of the membrane attack complex of complement and c3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
US10004707B2 (en) 2014-04-15 2018-06-26 Aurin Biotech Inc. Method for treating cancer with low molecular weight components of aurin tricarboxylic acid complex
US11013750B2 (en) 2017-01-20 2021-05-25 Aurin Biotech Inc. Methods for treating and preventing nociceptive pain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007270A (en) 1975-11-18 1977-02-08 American Cyanamid Company Complement inhibitors
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
US4880788A (en) 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5434185A (en) 1993-05-17 1995-07-18 The University Of Kentucky Research Foundation Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
DE4338793A1 (en) * 1993-11-12 1995-05-18 Froelich Juergen C L-arginine and analogues as platelet aggregation inhibitors
JP3110931B2 (en) 1993-12-28 2000-11-20 第一製薬株式会社 Argatroban preparation with smooth muscle cell growth inhibitory action
US5891645A (en) 1994-06-01 1999-04-06 Alexion Pharmaceuticals, Inc. Porcine E-selectin
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
WO2001057184A2 (en) * 2000-02-01 2001-08-09 Vanderbilt University Use of platelet activity modulators for inhibiting complement activation

Also Published As

Publication number Publication date
US20030144358A1 (en) 2003-07-31
US6538028B1 (en) 2003-03-25
WO2001057184A3 (en) 2002-04-25
WO2001057184A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001259056A1 (en) Method for selectively inhibiting ghrelin action
AU2001245283A1 (en) Methods for treating aneurysms
AU2001258771A1 (en) -secretase inhibitors
AU2001295030A1 (en) Adaptive method for polling
AU2002239660A1 (en) Watermaking holograms
AU2001231104A1 (en) Methods for treating diabetes
AU2002210881A1 (en) Transdermal method
AU2001234730A1 (en) Method for inhibiting complement activation
AU2002216966A1 (en) Sludge inerting method
AU2001227140A1 (en) Method for inhibiting apoptosis under ischemic condition
AU2001233699A1 (en) Method for selecting products
AUPR152100A0 (en) Method for treating coral
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001291313A1 (en) Process for making 3-amino-2-chloro-4-methylpyridine
AU2001229461A1 (en) Method for inhibiting a tumor
AU2002214487A1 (en) Method for inducing apoptiosis
AU2001237530A1 (en) Method
AU2224001A (en) Hologram forming method
AU2001243297A1 (en) Method for treating or preventing depression
AU2001241636A1 (en) Halotherapy method
AU2001230253A1 (en) Processing method
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2001267769A1 (en) Process
AU2002228911A1 (en) Methods for inhibiting pain
AU5552200A (en) Method